Direct-to-Consumer Genetic Tests Should Come With a Health Warning
By Jessica Cussins,
The Pharmaceutical Journal
| 01. 15. 2015
In late 2014, the Google-backed company 23andMe announced that it would start selling its direct-to-consumer (DTC) genetic test in Canada and the UK — despite being banned by the US Food and Drug Administration (FDA) from selling it in the United States following misleading marketing.
The genetic test provides information for around 108 health conditions for which some degree of evidence exists, including 44 inherited conditions, 12 drug responses, 12 genetic risk factors and 41 traits. Some conditions on the list are both obvious and innocuous. For example, hair colour, eye colour, and height are among the 41 traits. But many of the results are about important health conditions, and are clearly supposed to incite a change in behaviour.
Genetic testing is appropriate — and can be life saving — when doctors and genetic counsellors interpret complex results and map out the various courses of action. However, DTC genetic testing companies, such as 23andME, deliberately eschew the framework between clinician and patient. Under the banner of personal empowerment, DTC companies proclaim that their products confer a new level of control over one’s health, and that...
Related Articles
By Aileen Editha, The Conversation | 12.11.2024
By Staff, Reuters | 12.04.2024
The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals (VRTX.O), opens new tab and bluebird bio (BLUE.O), opens new tab to help increase patient access to their gene therapies.
The so-called...
By Staff, Center for Food Safety | 12.03.2024
Photo by Markus Winkler on Unsplash
SAN FRANCISCO—In a precedential victory for food and environmental safety, a federal district court ruled today that genetically engineered (GE) organisms must be regulated. The Court's ruling overturns the 2020 rule overhaul by the...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
